Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022210830 - ANTI-SARS-COV-2 ANTIBODY

Publication Number WO/2022/210830
Publication Date 06.10.2022
International Application No. PCT/JP2022/015813
International Filing Date 30.03.2022
IPC
C07K 16/10 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
A61K 39/395 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 31/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
C12N 1/15 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
1Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
14Fungi ; Culture media therefor
15modified by introduction of foreign genetic material
C12N 1/19 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
1Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
14Fungi ; Culture media therefor
16Yeasts; Culture media therefor
19modified by introduction of foreign genetic material
C12N 1/21 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
1Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
20Bacteria; Culture media therefor
21modified by introduction of foreign genetic material
CPC
A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies
A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
C07K 16/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses ; , e.g. hepatitis E virus
C12N 15/63
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
Applicants
  • 国立大学法人 富山大学 NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA [JP]/[JP]
  • 富山県 TOYAMA PREFECTURE [JP]/[JP]
  • 国立大学法人北海道大学 NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY [JP]/[JP]
Inventors
  • 小澤 龍彦 OZAWA Tatsuhiko
  • 岸 裕幸 KISHI Hiroyuki
  • 磯部 正治 ISOBE Masaharu
  • 黒澤 信幸 KUROSAWA Nobuyuki
  • 森永 芳智 MORINAGA Yoshitomo
  • 山本 善裕 YAMAMOTO Yoshihiro
  • 仁井見 英樹 NIIMI Hideki
  • 谷 英樹 TANI Hideki
  • 前仲 勝実 MAENAKA Katsumi
  • 橋口 隆生 HASHIGUGHI Takao
Agents
  • 高島 一 TAKASHIMA, Hajime
Priority Data
2021-05642330.03.2021JP
2021-08911927.05.2021JP
2021-09897014.06.2021JP
Publication Language Japanese (ja)
Filing Language Japanese (JA)
Designated States
Title
(EN) ANTI-SARS-COV-2 ANTIBODY
(FR) ANTICORPS ANTI-SARS-COV-2
(JA) 抗SARS-CoV-2抗体
Abstract
(EN) The present invention addresses the problem of providing a novel and effective antibody that binds to the spike protein of SARS-CoV-2, and in particular addresses the problem of providing an antibody that inhibits binding between SARS-CoV-2 and ACE2 or an antibody that inhibits the entry of SARS-CoV-2 into the cell. The present invention provides, for example, an antibody that has the following combination of complementarity-determining regions (CDRs) and that binds to the spike protein of SARS-CoV-2, or an antigen-binding fragment from said antibody: CDRH1, 2, and 3 and CDRL1, 2, and 3 composed of the amino acid sequences of SEQ ID NOS: 9, 10, 11, 20, 21, and 22.
(FR) La présente invention aborde le problème de la fourniture d'un nouvel anticorps efficace qui se lie à la protéine de spicule du SARS-CoV-2, et en particulier aborde le problème de la fourniture d'un anticorps qui inhibe la liaison entre le SARS-CoV-2 et ACE2 ou un anticorps qui inhibe l'entrée du SARS-CoV-2 dans la cellule. La présente invention concerne, par exemple, un anticorps qui a la combinaison suivante de régions déterminant la complémentarité (CDR) et qui se lie à la protéine de spicule du SARS-CoV-2, ou un fragment de liaison à l'antigène dudit anticorps : CDRH1, 2, et 3 et CDRL1, 2, et 3 composées des séquences d'acides aminés de SEQ ID NOS : 9, 10, 11, 20, 21 et 22.
(JA) 本発明は,SARS-CoV-2のスパイクタンパク質に結合する新規で有効な抗体を提供することを課題とし,特には,SARS-CoV-2とACE2との結合を阻害する抗体,又はSARS-CoV-2の細胞内への侵入を阻害する抗体を提供することを課題とする。本発明は,例えば,以下の組み合わせの相補性決定領域(CDR)を有し,かつ,SARS-CoV-2スパイクタンパク質に結合する抗体又はその抗原結合性断片を提供する:配列番号9,10,11,20,21,及び22のアミノ酸配列からなるCDRH1,2,3,CDRL1,2,及び3。
Latest bibliographic data on file with the International Bureau